180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has been granted until July 31, 2021, to regain compliance with Nasdaq’s listing rule relating to untimely filings of its annual report for the year ended Dec. 31, 2020. The company had previously announced it had received notification from Nasdaq regarding compliance issues and filing the report with the Securities and Exchange Commission (“SEC”). The company is working to file the appropriate reports as soon as possible in order to retain compliance. 180 Life Sciences also announced that it has joined the Russell Microcap(R) Index; its status in the index becomes effective June 28, 2021. The company noted that membership in the index involves automatic inclusion in specific growth and value style indexes; the membership is valid for one year. Russell indexes are commonly used by investment managers and institutional investors as benchmarks for active investment strategies, with an estimated $10.6 trillion in assets benchmarked against its indexes. Russell indexes are part of FTSE Russell, a leading global index provider, which determines membership for its Russell indexes through evaluating market-capitalization rankings and style attributes. “The Russell indexes are widely used investment benchmarks for index funds and active portfolio strategies,” said 180 Life Sciences CEO Dr. James Woody in the press release. “Our inclusion is an important validation and should help our efforts to propel long-term shareholder value, expand awareness of 180 Life Sciences within the investment community, increase the liquidity of our stock, and broaden our shareholder base.”
To view the full press releases, visit https://ibn.fm/gPxm9 and https://ibn.fm/cmmUd
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. 180 Life Sciences’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.